Oncology Deal-Making The Daiichi Way
$13bn Deal Value In 18 Months
Executive Summary
Daiichi Sankyo’s relatively young strategic pivot into oncology is paying major dividends, with two huge global deals with AstraZeneca now in the bag within 18 months. Scrip takes a closer look with the help of insights from the Japanese firm’s global oncology R&D head.
You may also be interested in...
Asia Deal Watch: Perceptive Launches LianBio With “China-Centric” Strategy
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
Asia Deal Watch: Simcere, G1 Partner Globally On Myelopreservation Drug
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.